Market Access: Pharma

Mock Negotiations and Payer Consultations

Full-service solutions tailored to your needs

Alira Health provides a range of mock negotiation and payer consultation solutions to deliver commercial success, including:
  • Generation of integrated payer evidence and analyses plans to support market access and P&R
  • Preparation and facilitation of international payer-expert advisory boards to optimize development programs and gather insights on product value and evidence requirements
  • Design and facilitation of product value workshops with cross-functional and international teams
  • Payer/Health Technology Assessment (HTA) landscape assessments

Why choose Alira Health?

As your partner, we’ll work closely with you to uncover opportunities across the pharma industry, accelerate innovation, and deliver tomorrow’s standard of care. You’ll benefit from our:

  • Access to a diverse

    integrated team with deep industry expertise

  • Close collaboration

    with our regulatory and clinical

  • Specific, local insights

    as part of your larger, global strategy—a benefit of having market access teams in both the EU and U.S.

Working together to transform healthcare

Whether you need to understand which asset best aligns with your long-term strategy, which new market or therapeutic area to explore, or how to expand into another sector, we are ready to help you lead the way.

Contact us
Jean-François Ricci
Jean-François Ricci
Executive Vice President, Global Market Access
Our strong client partnerships allow us to deliver in-depth, customized strategies and access solutions—all designed to maximize product value across its full lifecycle.

Related News

Due Diligence MedTech Patient Engagement Pharma
Multimedia April 12, 2021
Evolution of the Drug Delivery Systems Industry and its Increasing Role in Driving Patient Outcomes
In the third episode, Amira Ghozali, Aptar Pharma, Kenny Carberry, and Aude Ouensanga, discuss the evolution of the DDS industry, its relationship with Pharma, and its increasing role(...)
M&A
Publications February 28, 2021
What’s most important when selecting a firm for your next transaction?
These are just a few of the critical factors that can help you select the right advisory firm for your next deal, whether you’re looking to license, acquire, or sell.
M&A
Publications February 24, 2021
What You Should Know Before Choosing a Healthcare Transaction Advisory Firm
What’s most important when selecting a firm for your next transaction? Global experience, staff profiles, technical expertise? To learn more download our latest TAD Infographic.
MedTech Pharma
Publications February 8, 2021
Infographic: 2021 Trends in Healthcare
It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.
MedTech Pharma
News February 4, 2021
2020 Year in Review
With 2021 in full swing, we want to take a moment to reflect on last year’s achievements and congratulate the entire Alira Health Team for their hard work and dedication to healthcare(...)
M&A Pharma
News December 20, 2020
We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS
We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.
Pharma
News December 15, 2020
Welcome Daniela Sica, Vice President, Business Development, Pharma and Biotech
We are pleased to announce that Daniela Sica has joined the firm as Vice President, Business Development, Pharma and Biotech.

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.